HUP0401153A2 - Epothilone-származékokat tartalmazó kombinációk és azok gyógyszerészeti felhasználása - Google Patents
Epothilone-származékokat tartalmazó kombinációk és azok gyógyszerészeti felhasználásaInfo
- Publication number
- HUP0401153A2 HUP0401153A2 HU0401153A HUP0401153A HUP0401153A2 HU P0401153 A2 HUP0401153 A2 HU P0401153A2 HU 0401153 A HU0401153 A HU 0401153A HU P0401153 A HUP0401153 A HU P0401153A HU P0401153 A2 HUP0401153 A2 HU P0401153A2
- Authority
- HU
- Hungary
- Prior art keywords
- combination
- delaying
- progression
- pharmaceutically acceptable
- alkyl group
- Prior art date
Links
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya gyógyszer-kombináció, melyet (a) egy biszfoszfonát,egy platinavegyület vagy egy vasculosztatikus vegyület és (b) valamely(I) általános képletű epothiloneszármazék - ahol a képletben Ajelentése oxigénatom vagy NRN általános képletű csoport, melyben RNjelentése hidrogénatom vagy rövid szénláncú alkilcsoport, R jelentésehidrogénatom vagy rövid szénláncú alkilcsoport, és Z jelentéseoxigénatom vagy vegyértékvonal - alkot, amely kombinációban az (a) és(b) hatóanyagok minden esetben szabad formában vagy gyógyszerészetilegelfogadható só formájában vannak jelen, és a kombináció adott esetbenlegalább egy gyógyszerészetileg elfogadható hordozóanyagot tartalmaz.A kombináció (a) és (b) partnereit alkalmazhatják egyidejűleg,elkülönítve vagy egymás után adagolva, különösen proliferatívbetegség, speciálisan szilárd tumor betegség kezelésében vagyprogressziójának késleltetésében. A találmány további tárgya ekombinációt tartalmazó gyógyszerkészítmény, kereskedelmi kiszerelésvagy termék; a kombináció felhasználása proliferatív betegségkezelésére vagy progressziójának késleltetésére alkalmas gyógyszerelőállítására. Ó
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30655901P | 2001-07-19 | 2001-07-19 | |
US30657101P | 2001-07-19 | 2001-07-19 | |
US30656001P | 2001-07-19 | 2001-07-19 | |
PCT/EP2002/008020 WO2003007924A2 (en) | 2001-07-19 | 2002-07-18 | Combinations comprising epothilones and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401153A2 true HUP0401153A2 (hu) | 2004-10-28 |
HUP0401153A3 HUP0401153A3 (en) | 2008-01-28 |
Family
ID=27405180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401153A HUP0401153A3 (en) | 2001-07-19 | 2002-07-18 | Combinations comprising epothilones and pharmaceutical uses thereof |
Country Status (19)
Country | Link |
---|---|
US (3) | US20040235796A1 (hu) |
EP (2) | EP1412029A2 (hu) |
JP (2) | JP2005501825A (hu) |
KR (2) | KR20090040925A (hu) |
CN (2) | CN1283248C (hu) |
AU (2) | AU2002328921B2 (hu) |
BR (1) | BR0211271A (hu) |
CA (1) | CA2453108A1 (hu) |
CO (1) | CO5560565A2 (hu) |
EC (2) | ECSP084948A (hu) |
HU (1) | HUP0401153A3 (hu) |
IL (2) | IL159517A0 (hu) |
MX (1) | MXPA04000567A (hu) |
NO (1) | NO20040214L (hu) |
NZ (2) | NZ530572A (hu) |
PL (1) | PL365030A1 (hu) |
RU (1) | RU2375058C2 (hu) |
TW (1) | TWI315982B (hu) |
WO (1) | WO2003007924A2 (hu) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
JP2004529904A (ja) | 2001-03-14 | 2004-09-30 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
ES2324917T3 (es) | 2003-11-18 | 2009-08-19 | Novartis Ag | Inhibidores de la forma mutante de kit. |
US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
US20080176879A1 (en) | 2005-05-02 | 2008-07-24 | Leila Alland | Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis |
CN100384419C (zh) * | 2005-12-02 | 2008-04-30 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素缓释植入组合物及应用 |
EA035193B1 (ru) | 2010-05-18 | 2020-05-14 | Серулин Фарма Инк. | Композиции и способы лечения аутоиммунных и других заболеваний |
RU2478407C1 (ru) * | 2011-09-05 | 2013-04-10 | Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) | Способ комбинированного лечения местно-распространенного рака желудка |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2409754A (en) * | 1946-10-22 | Method for obtaining hydantoins | ||
US3475486A (en) * | 1966-09-12 | 1969-10-28 | Monsanto Co | Process for preparing phosphonic acids |
NL7304882A (hu) | 1972-04-10 | 1973-10-12 | ||
CH605550A5 (hu) | 1972-06-08 | 1978-09-29 | Research Corp | |
DE2405254C2 (de) * | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
FR2531088B1 (fr) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
FR2694558B1 (fr) * | 1992-08-05 | 1994-10-28 | Sanofi Elf | Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant. |
DE69233739D1 (de) | 1992-10-28 | 2008-08-07 | Genentech Inc | Verwendung von Antagonisten des Zellwachstumsfaktors VEGF |
CA2151240A1 (en) | 1992-12-23 | 1994-07-07 | Donna T. Whiteford | Biophosphonate/estrogen therapy for treating and preventing bone loss |
ES2152412T3 (es) | 1994-08-08 | 2001-02-01 | Debiopharm Sa | Preparacion farmaceuticamente estable de oxaliplatino. |
DK0833643T3 (da) * | 1995-06-06 | 2005-05-30 | Merck & Co Inc | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
ATE218556T1 (de) * | 1995-11-17 | 2002-06-15 | Biotechnolog Forschung Gmbh | Epothilon-derivate und deren herstellung |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
NZ335383A (en) | 1996-11-18 | 2000-10-27 | Biotechnolog Forschung Gmbh | Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells |
DE69734362T2 (de) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ES2324378T3 (es) * | 1998-02-05 | 2009-08-05 | Novartis Ag | Composicion farmaceutica que contiene epotilona. |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
WO2000000485A1 (de) * | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
CA2350189A1 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
CA2355976C (en) | 1998-12-22 | 2012-07-17 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
SK287357B6 (sk) | 1999-02-12 | 2010-08-09 | The Scripps Research Institute | Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz |
DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
GB9907908D0 (en) * | 1999-04-07 | 1999-06-02 | Bataille Regis | Organic compounds |
WO2000071104A2 (en) * | 1999-05-21 | 2000-11-30 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
EP1267888A4 (en) * | 2000-01-04 | 2005-12-28 | Univ California | USE OF LOW-DOSEED BISPHOSPHONATES FOR PREVENTING THE CALIBRATION OF HEART AND ARTERIES |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
JP4837864B2 (ja) | 2000-02-09 | 2011-12-14 | ノバルティス アーゲー | 血管形成および/またはvegf受容体チロシンキナーゼを阻害するピリジン誘導体 |
JP2004529904A (ja) | 2001-03-14 | 2004-09-30 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
-
2002
- 2002-07-17 TW TW091115929A patent/TWI315982B/zh not_active IP Right Cessation
- 2002-07-18 US US10/484,482 patent/US20040235796A1/en not_active Abandoned
- 2002-07-18 MX MXPA04000567A patent/MXPA04000567A/es active IP Right Grant
- 2002-07-18 CN CNB028144147A patent/CN1283248C/zh not_active Expired - Fee Related
- 2002-07-18 NZ NZ530572A patent/NZ530572A/en not_active IP Right Cessation
- 2002-07-18 EP EP02764726A patent/EP1412029A2/en not_active Withdrawn
- 2002-07-18 KR KR1020097006647A patent/KR20090040925A/ko not_active Application Discontinuation
- 2002-07-18 HU HU0401153A patent/HUP0401153A3/hu unknown
- 2002-07-18 CN CN200910168406A patent/CN101791308A/zh active Pending
- 2002-07-18 EP EP10157876A patent/EP2210643A3/en not_active Withdrawn
- 2002-07-18 IL IL15951702A patent/IL159517A0/xx unknown
- 2002-07-18 JP JP2003513533A patent/JP2005501825A/ja not_active Withdrawn
- 2002-07-18 KR KR10-2004-7000700A patent/KR20040030808A/ko not_active Application Discontinuation
- 2002-07-18 PL PL02365030A patent/PL365030A1/xx not_active IP Right Cessation
- 2002-07-18 BR BR0211271-0A patent/BR0211271A/pt not_active Application Discontinuation
- 2002-07-18 WO PCT/EP2002/008020 patent/WO2003007924A2/en active Application Filing
- 2002-07-18 AU AU2002328921A patent/AU2002328921B2/en not_active Ceased
- 2002-07-18 RU RU2004105144/15A patent/RU2375058C2/ru not_active IP Right Cessation
- 2002-07-18 NZ NZ550174A patent/NZ550174A/en not_active IP Right Cessation
- 2002-07-18 CA CA002453108A patent/CA2453108A1/en not_active Abandoned
-
2003
- 2003-12-22 IL IL159517A patent/IL159517A/en not_active IP Right Cessation
-
2004
- 2004-01-16 NO NO20040214A patent/NO20040214L/no not_active Application Discontinuation
- 2004-02-11 CO CO04011525A patent/CO5560565A2/es not_active Application Discontinuation
-
2005
- 2005-12-20 AU AU2005246964A patent/AU2005246964B2/en not_active Ceased
-
2008
- 2008-01-24 US US12/019,294 patent/US7612052B2/en not_active Expired - Fee Related
- 2008-07-04 EC EC2008004948A patent/ECSP084948A/es unknown
-
2009
- 2009-08-28 US US12/549,947 patent/US8008330B2/en not_active Expired - Fee Related
- 2009-11-19 EC EC2009004948A patent/ECSP094948A/es unknown
-
2010
- 2010-03-01 JP JP2010044000A patent/JP2010159271A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303016A2 (hu) | Xantin foszfodiészteráz V inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0401153A2 (hu) | Epothilone-származékokat tartalmazó kombinációk és azok gyógyszerészeti felhasználása | |
HUP0300826A2 (hu) | Egy epotilon-analóg polimorfjai, eljárás az elżállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303128A2 (hu) | O-dezmetil-venlafaxin új szukcinátsója, eljárás az előállításukra, alkalmazása és ezt tartalmazó gyógyszerkészítmény | |
HUP0402191A2 (hu) | Humán metabotrop glutamát receptor antagonista aktivitással rendelkező acetilénszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
MXPA05008148A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). | |
CA2498047A1 (en) | Novel imidazole compounds as transforming growth factor (tgf) inhibitors | |
MXPA05009245A (es) | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). | |
HUP0400442A2 (hu) | Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására | |
GEP20063895B (en) | Platinum derivative pharmaceutical formulations | |
MY136430A (en) | N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation | |
HUP0400782A2 (hu) | Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények | |
HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
HUP0300057A2 (en) | Glucopyranosyloxy benzylbenzene derivatives, pharmaceutical compositions containing the same and intermediates for the preparation of the derivatives | |
SE0104341D0 (sv) | New use | |
HUP0203818A2 (hu) | Fungicid hatású (trifluor-metil)-pirrol-karboxamidok és (trifluor-metil)-pirrol-tioamidok, előállításuk és alkalmazásuk | |
EP1725536B8 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
HUP0300080A2 (hu) | Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények | |
DE60034240D1 (de) | Drogen zur behandlung maligner tumoren | |
DE60205455D1 (de) | Naphthyridinderivate | |
HUP0300701A2 (hu) | Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények | |
YU7804A (sh) | Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova | |
MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
HUP0401403A2 (hu) | 2,4-Diamino-tiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
SE0102440D0 (sv) | New compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |